FDA OKs Dapagliflozin as Type 2 Drug

| Jan 9, 2014

The Food and Drug Administration has approved the entry of dapagliflozin, a drug for treating type 2 diabetes, into the U.S. market.

Dapagliflozin, manufactured by Bristol-Myers Squibb and AstraZeneca, will be sold under the brand name Farxiga.

The drug belongs to a new class of type 2 medications called SGLT-2 (sodium glucose co-transporter 2) inhibitors that block the reabsorption of glucose by the kidney and sends it to the urinary tract. By helping the body excrete glucose, the drug lowers blood sugar levels.

However, the FDA's approval is not unconditional. The agency has told Bristol-Myers and AstraZeneca that they must conduct six post market-introduction studies to bolster the drug's safety profile. They include:

• an outcomes trial in patients with cardiovascular disease risks

• a bladder cancer risk trial

• an animal study of drug-induced urinary flow and bladder tumor risk

• two trials on risks children

• a program to study liver abnormalities and effects on pregnancy

Dapagliflozin is not the first SGLT-2 inhibitor on the U.S. market. In 2012, the FDA approved Janssen Pharmaceutical's Invokana, an SGLT-2 inhibitor called canagliflozin.

The drug was tested in 16 clinical trials that involved more than 9,400 type 2 patients. It should not be taken at all by type 1 patients, or by type 2s who have a high presence of ketones in their blood or urine, any sort of renal impairment, end-stage renal disease, or are on dialysis. Bladder cancer patients also cannot take dapagliflozin.

A Personal Note

Over the past four years, I have been involved in two Phase 3 studies of dapagliflozin. The first study, which ended in early 2012, was aimed at seeing how the drug affected my A1c's. Over the course of my one-year participation in the study, my A1c dropped 0.5% and I lost 10 lbs. of weight. I experienced no side effects, and was not even aware that I was visiting the bathroom once or twice more often each day.

I had been told that some weight loss was typical for most users of the drug. But I can't say that my drop in A1c numbers or slight weight loss could be attributed to dapagliflozin. In conjunction with taking the drug, I also followed a diet and exercise routine designed to control blood sugars.

My second participation in a dapagliflozin study started six months ago (mid-July, 2013) and is slated to last six years. It's the study on cardiovascular outcomes, namely, do dapagliflozin users run a higher risk of heart attack or stroke from taking the drug?

I volunteered for the study because of my first good experience with the drug and because my endocrinologist is a humorous, fascinating, well-read man who does as much as anybody to keep me plugged in to diabetes research. A third reason is that I'm complimented that the people conducting the study are confident that I, a man in his 60s, will still be around in 2019.

Click Here To View Or Post Comments

Categories: AstraZeneca, Bristol-Meyers Squibb, Canagliflozin, Dapagliflozin, Farxiga, SGLT-2 Inhibitors


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Jan 9, 2014

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.